FeesSafety
Pluang+

Neuronetics Q3 revenue rises 12.5% with improved profitability and new FDA submissions

Company Fundamentals
04 Nov 2026, 14:50 WIB
GlobeNewsWire
View Source
Bullish
Neuronetics Q3 revenue rises 12.5% with improved profitability and new FDA submissions

Neuronetics reported a 12.5% revenue increase to $42 million in Q3 2026, driven by 20.1% growth in its Greenbrook clinics. The company improved adjusted EBITDA to $1.9 million from a loss last year and reduced its net loss to $1.6 million. Key developments include submitting a 510(k) application for accelerated TMS and partnering with Wave Neuro for PTSD treatment. Neuronetics also launched the first TMS integration with an EHR/EMR platform, aiming to expand patient access and operational efficiency.

Neuronetics' Q3 2026 results provide context for readers. For those tracking the health sector, 118 of 150 US health stocks on Pluang rose while 24 fell. Notable movers include ABEO at USD 4.41 with a 3.76% gain, TMDX at USD 69.85 up 3.73%, and RXRX at USD 3.81 rising 3.53%, as of Nov 04, 2026 18:41 WIB.

More News

Good Life Meds must stop unproven health and personalization claims for compounded Tirzepatide+ products.

Good Life Meds must stop unproven health and personalization claims for compounded Tirzepatide+ products.

The National Advertising Division (NAD) recommended that Good Life Meds discontinue claims about health benefits and personalization for its compounded Tirzepatide+ weight loss products after a challenge by Eli Lilly. NAD found that Good Life lacked ...

Market News
Bearish
25 minutes ago
Moleculin's Annamycin shows promising remission rates in AML trial, data to be presented at ASH 2026.

Moleculin's Annamycin shows promising remission rates in AML trial, data to be presented at ASH 2026.

Moleculin Biotech announced that interim results from its Phase 2/3 trial of Annamycin for relapsed or refractory acute myeloid leukemia (AML) will be presented at the 2026 ASH Annual Meeting. The trial showed remission rates of 43% and 36% in two An...

Company Fundamentals
Bullish
25 minutes ago
ANZ dental implants market to grow 5% CAGR, reaching $393M by 2033 driven by aging population and prosthetic demand

ANZ dental implants market to grow 5% CAGR, reaching $393M by 2033 driven by aging population and prosthetic demand

The Australia and New Zealand (ANZ) dental implants market, valued at $266 million in 2025, is projected to grow at a 5% CAGR to $393 million by 2033. Growth is driven by increasing demand for oral rehabilitation and prosthetic dentistry, especially ...

Market News
Bullish
25 minutes ago
New study shows Asgard's tech induces cancer-fighting structures in tumors, boosting therapy success across 7 cancer types.

New study shows Asgard's tech induces cancer-fighting structures in tumors, boosting therapy success across 7 cancer types.

Asgard Therapeutics published a study in Immunity demonstrating its technology can reprogram tumor cells into dendritic cells, inducing cancer-fighting tertiary lymphoid structures (imgTLSs) across seven tumor types. This tumor-agnostic approach led ...

Others
Bullish
25 minutes ago
Cap expands onchain credit marketplace to finance film production without tokenizing assets

Cap expands onchain credit marketplace to finance film production without tokenizing assets

Cap, an onchain credit marketplace, is expanding into film and media financing by providing funding for the upcoming film Wake. This deal uses advances against anticipated film production tax credits, showing how Cap's underwriting model supports spe...

Market News
Bullish
25 minutes ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App